AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 34 min read$PFE

Pfizer's Revenue Barely Moved. Its Forecast Just Went Higher

Pfizer (PFE) reported Q3 revenue of $16.6B, slightly down YoY but above estimates. Adjusted EPS was $0.87, exceeding forecasts. COVID-19 vaccine and Paxlovid sales declined, but Eliquis and Padcev saw growth. Pfizer raised its 2023 revenue outlook to $62B-$64B and EPS to $2.95-$3.05. The company also appointed a new CFO.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 4:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 4:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Pfizer's Revenue Barely Moved. Its Forecast Just Went Higher — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$PFEBullishMed
01

Why it matters

The key tradable update is the raised 2026 revenue and adjusted EPS outlook following a Q3 beat, signaling improved visibility for non-COVID revenue streams.

02

Market read

Guidance lift after a Q3 beat can drive near-term repricing of Pfizer’s 2026 earnings power, especially for investors focused on the COVID-to-oncology transition.

03

What to watch

The article highlights product mix changes but does not quantify competitive, pricing, or pipeline risks that could cap the durability of the new forecast.

Relevance 8/10Novelty 7/10Timing: post-Q3, guidance update reported today

Background

Pfizer’s COVID franchise (Comirnaty and Paxlovid) continues to decline, while growth is shifting toward Eliquis and oncology drug Padcev.

Company-level read

Ticker impact

$PFEBullishHigh confidence
Context

Pfizer raised its 2026 revenue outlook to $62B-$64B after Q3 results beat expectations, despite COVID portfolio declines.

Expected impact

Likely upward bias as the market reprices Pfizer’s 2026 revenue and EPS trajectory toward the raised forecast.

Evidence & confidence

The article cites a specific guidance increase (revenue and adjusted EPS) tied to Q3 outperformance and mix shift away from declining COVID products.

Market effects

Sector

Reinforces a broader read-through that oncology and key franchise drugs can stabilize pharma earnings as COVID demand fades.

Regional

Primarily US large-cap pharma sentiment; limited direct spillover beyond peers watching COVID-to-oncology transition.

Global

Guidance-driven repricing can influence global pharma risk appetite, especially for companies with similar COVID exposure.

Counterpoint

What could challenge this read

Raised guidance may still be vulnerable if Eliquis and Padcev growth cannot fully compensate for continued COVID portfolio declines through 2027.

Key entities

  • company
    Pfizer Inc.

    Raised 2026 revenue forecast to $62B-$64B and adjusted EPS to $2.95-$3.05 after Q3 beat.

  • product
    Comirnaty

    COVID vaccination sales down 29% year over year, per the article.

  • product
    Paxlovid

    COVID treatment revenue down 63% year over year, per the article.

  • product
    Eliquis

    Revenue grew 25% year over year, per the article.

  • product
    Padcev

    Sales surged 55% year over year, per the article.

Read at source← All news

StoryPfizer beats Q3 expectations, raises 2026 guidance and appoints new CFO

Also covered by

3 outlets

Related articles

NOV 3
$PFEMedAI 8/10

Pfizer Reports R&D Pipeline Progress as Next CFO Confirmed

Pfizer reported Q3 2026 revenue of $16.6bn, flat YoY but up 7% excluding COVID-19 products. It raised full-year revenue guidance to $62bn-$64bn. The company highlighted R&D progress and strong growth in launched/acquired products. Cecile Guegan was confirmed as permanent CFO. Pfizer's strategy includes acquisitions like Seagen and Metsera to drive future growth.

healthcare-digital.com5 min
NOV 3
$PFEHighAI 9/10

[Pfizer Q3 2026 Earnings Call] Pfizer Lifts 2026 Revenue Guidance by $1.5 Billion to $62–$64 Billion as Non-COVID Sales Grow 7% and Launched Products Surge 32%

Pfizer raised its 2026 revenue guidance by $1.5B to $62-64B, citing 7% growth in non-COVID sales and 32% surge in launched products. Q3 revenue was $16.6B, beating expectations, with adjusted EPS at $0.87. Key products like PADCEV and NURTEC drove growth, while COVID-19 sales declined. The company plans $2.5B in additional savings by 2027-2029.

finance.biggo.com7 min
NOV 3
$PFEMedAI 9/10

PFE Beats Q3 Earnings & Sales Estimates, Raises 2026 Guidance

Pfizer (PFE) reported Q3 2026 adjusted EPS of $0.87, beating estimates of $0.72, with revenues of $16.58B, also surpassing expectations. Growth in Eliquis, Padcev, and other drugs offset declines in COVID-19 products. PFE raised 2026 guidance to $62.0B-$64.0B in revenue and $2.95-$3.05 in EPS, citing strong performance. Shares declined slightly in pre-market trading.

theglobeandmail.com7 min
NOV 3
$PFEHighAI 9/10

Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results

Pfizer raised its 2023 profit and revenue forecasts due to strong demand for Eliquis and cancer drug Padcev. It now expects $62B-$64B in sales and $2.95-$3.05 EPS. CEO Albert Bourla cited strong Q3 performance and confidence in the pipeline. The company has invested heavily in acquisitions, including Seagen and Metsera. Pfizer reported Q3 adjusted profit of $0.87 per share, above estimates, with revenue of $16.58B. Eliquis sales rose 25% to $2.52B.

bdnews24.com6 min